Preprint
Machine Learning

Discovery of small molecule cancer drugs: Successes, challenges and opportunities

Swen Hoelder(Institute of Cancer Research), Paul A. Clarke(Institute of Cancer Research), Paul Workman(Institute of Cancer Research)
March 3, 2012Molecular Oncology585 citations
PDFDOI

585

Citations

10

Influential Citations

Molecular Oncology

Venue

2012

Year

Abstract

The discovery and development of small molecule cancer drugs has been revolutionised over the last decade. Most notably, we have moved from a one-size-fits-all approach that emphasized cytotoxic chemotherapy to a personalised medicine strategy that focuses on the discovery and development of molecularly targeted drugs that exploit the particular genetic addictions, dependencies and vulnerabilities of cancer cells. These exploitable characteristics are increasingly being revealed by our expanding understanding of the abnormal biology and genetics of cancer cells, accelerated by cancer genome sequencing and other high-throughput genome-wide campaigns, including functional screens using RNA interference. In this review we provide an overview of contemporary approaches to the discovery of small molecule cancer drugs, highlighting successes, current challenges and future opportunities. We focus in particular on four key steps: Target validation and selection; chemical hit and lead generation; lead optimization to identify a clinical drug candidate; and finally hypothesis-driven, biomarker-led clinical trials. Although all of these steps are critical, we view target validation and selection and the conduct of biology-directed clinical trials as especially important areas upon which to focus to speed progress from gene to drug and to reduce the unacceptably high attrition rate during clinical development. Other challenges include expanding the envelope of druggability for less tractable targets, understanding and overcoming drug resistance, and designing intelligent and effective drug combinations. We discuss not only scientific and technical challenges, but also the assessment and mitigation of risks as well as organizational, cultural and funding problems for cancer drug discovery and development, together with solutions to overcome the 'Valley of Death' between basic research and approved medicines. We envisage a future in which addressing these challenges will enhance our rapid progress towards truly personalised medicine for cancer patients.

Analysis

Why This Paper Matters

This review is a landmark synthesis of the paradigm shift in cancer drug discovery from cytotoxic chemotherapy to personalized, molecularly targeted therapies. Published in 2012, it captures a critical inflection point where cancer genomics and functional screens were beginning to reveal actionable vulnerabilities. The paper's emphasis on target validation and biomarker-driven clinical trials directly addresses the high attrition rates that plagued drug development, making it essential reading for both academic and industrial researchers.

The authors, from the Institute of Cancer Research in London, bring authoritative perspective on the 'Valley of Death'—the gap between basic research and approved medicines. By systematically outlining challenges such as druggability, resistance, and combination therapy design, the paper provides a roadmap for future investment and innovation. Its 585 citations reflect its enduring relevance as a foundational reference.

Technical Contributions

  • Target Validation Framework: Emphasizes genetic addictions and dependencies revealed by cancer genome sequencing and RNA interference screens as the basis for selecting high-value targets.
  • Hit and Lead Generation: Discusses high-throughput screening, fragment-based approaches, and structure-based design for identifying chemical starting points.
  • Lead Optimization: Covers medicinal chemistry strategies to improve potency, selectivity, and pharmacokinetics while mitigating toxicity.
  • Biomarker-Led Trials: Advocates for hypothesis-driven clinical development with predictive biomarkers to enrich patient populations and reduce late-stage failures.
  • Druggability Expansion: Identifies strategies for targeting historically undruggable proteins (e.g., protein-protein interactions, transcription factors) using novel modalities.

Results

As a review, the paper does not present new experimental results. However, it synthesizes key success stories (e.g., imatinib, gefitinib) and quantifies the attrition problem: only about 5% of oncology drugs entering Phase I trials eventually gain approval. The authors argue that improved target validation could double this success rate. They also note that biomarker-stratified trials have shown higher response rates in molecularly selected patient subgroups.

Significance

This paper has shaped the strategic thinking of drug discovery teams by providing a structured analysis of bottlenecks and solutions. Its call for better target validation and biomarker integration has been widely adopted, influencing both academic research priorities and industry R&D models. The concept of the 'Valley of Death' has become a standard term in translational research discussions. For AI practitioners, the paper underscores the need for computational tools in target identification, chemical library design, and predictive modeling of drug properties—areas where machine learning is now making substantial contributions.

drug-discoverycancerpersonalized-medicinetarget-validationlead-optimizationbiomarkersclinical-trials

Related Papers